Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials.
Saved in:
| Title: | Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials. |
|---|---|
| Authors: | Bender Ignacio RA; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle.; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington., Chew KW; Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, UCLA (University of California, Los Angeles)., Moser C; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Currier JS; Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, UCLA (University of California, Los Angeles)., Eron JJ; Division of Infectious Diseases, Department of Medicine, The University of North Carolina School of Medicine, Chapel Hill., Javan AC; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland., Giganti MJ; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Aga E; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Gibbs M; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Tchouakam Kouekam H; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Toronto, Ontario, Canada., Johnsson E; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Esser MT; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland., Hoover K; Miami Clinical Research and Baptist Health South Florida, Miami., Neytman G; Quantum Clinical Trials, Miami Beach, Florida., Newell M; Division of Infectious Diseases, Department of Medicine, The University of North Carolina School of Medicine, Chapel Hill., Daar ES; Division of HIV Medicine, Lundquist Institute, Harbor-UCLA Medical Center, Los Angeles, California., Fischer W; Division of Pulmonary Diseases and Critical Care Medicine, The University of North Carolina School of Medicine, Chapel Hill., Fletcher CV; UNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha., Li JZ; Division of Infectious Diseases, Department of Medicine, Harvard Medical School, Boston, Massachusetts., Greninger AL; Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle., Coombs RW; Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle., Hughes MD; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Smith D; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego., Wohl DA; Division of Infectious Diseases, Department of Medicine, The University of North Carolina School of Medicine, Chapel Hill. |
| Corporate Authors: | Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)–2/A5401 Study Team |
| Source: | JAMA network open [JAMA Netw Open] 2023 Apr 03; Vol. 6 (4), pp. e2310039. Date of Electronic Publication: 2023 Apr 03. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet ISSN: 2574-3805 (Electronic) Linking ISSN: 25743805 NLM ISO Abbreviation: JAMA Netw Open Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2574-3805 |
|---|---|
| DOI: | 10.1001/jamanetworkopen.2023.10039 |
